DPP-4 inhibitors × glycemic control

TrialEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.

Sung-Chen Liu et al.PubMed ↗Publisher ↗

What the trial testedas reported · 119 people

No range given

Reported higher glycemic control, no range given

+5.70mg/dL

As reported

difference 5.7 mg/dL, no interval

+2 more in the walkthrough ↓

Three numbers in the abstract

the abstract, start to end

a between-groups difference of -0.23 ± 0.16% (P = .16).

a between-groups difference of -12.9 ± 5.7 mg/dL (P = .02).

with a between-group difference of 1.6 kg (P<.01).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
0.16
Glycemic control
5.7
Body weight & composition
1.6
DPP-4 inhibitorsThiazolidinedionesGlycemic controlBody weight & composition
1 / 4

15 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
pooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 23807528